Nykode Therapeutics AS (OSL:NYKD)
Norway · Delayed Price · Currency is NOK 1.477
-0.023 (-1.53%)
Sep 17, 2025, 1:39 PM CET
Nykode Therapeutics AS Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 7.31 | 8.68 | 12.9 | 7.17 | 33.96 | 215 | Upgrade |
Other Revenue | 0.59 | 0.48 | 0.42 | 1.86 | 1.8 | 0.7 | Upgrade |
| 7.89 | 9.16 | 13.32 | 9.03 | 35.77 | 215.7 | Upgrade | |
Revenue Growth (YoY) | 21.13% | -31.26% | 47.56% | -74.76% | -83.42% | 15175.85% | Upgrade |
Gross Profit | 7.89 | 9.16 | 13.32 | 9.03 | 35.77 | 215.7 | Upgrade |
Selling, General & Admin | 23.61 | 31.55 | 28.42 | 18.8 | 17.51 | 16.41 | Upgrade |
Other Operating Expenses | 17.3 | 23.69 | 40.87 | 41.57 | 28.3 | 20.72 | Upgrade |
Operating Expenses | 43.05 | 57.49 | 71.41 | 62.19 | 46.54 | 37.43 | Upgrade |
Operating Income | -35.16 | -48.33 | -58.08 | -53.16 | -10.78 | 178.27 | Upgrade |
Interest Expense | -0.15 | -0.19 | -0.22 | -0.24 | -0.13 | -0.05 | Upgrade |
Interest & Investment Income | 5.65 | 7 | 8.95 | 3.69 | 0.27 | 0.2 | Upgrade |
Currency Exchange Gain (Loss) | 5.41 | -4 | 5.27 | -1.24 | -0.63 | 2.63 | Upgrade |
Other Non Operating Income (Expenses) | - | - | - | -0.14 | 0.03 | -0.21 | Upgrade |
EBT Excluding Unusual Items | -24.25 | -45.51 | -44.09 | -51.09 | -11.23 | 180.84 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | 0.1 | 0.12 | 0.07 | Upgrade |
Pretax Income | -24.25 | -45.51 | -44.09 | -50.98 | -11.12 | 180.9 | Upgrade |
Income Tax Expense | -7.18 | -6.69 | -8.93 | -8.24 | -1.7 | 31.13 | Upgrade |
Net Income | -17.07 | -38.82 | -35.15 | -42.74 | -9.41 | 149.77 | Upgrade |
Net Income to Common | -17.07 | -38.82 | -35.15 | -42.74 | -9.41 | 149.77 | Upgrade |
Shares Outstanding (Basic) | 327 | 327 | 301 | 290 | 286 | 280 | Upgrade |
Shares Outstanding (Diluted) | 327 | 327 | 301 | 290 | 286 | 296 | Upgrade |
Shares Change (YoY) | 1.97% | 8.66% | 3.58% | 1.32% | -3.31% | 1.14% | Upgrade |
EPS (Basic) | -0.05 | -0.12 | -0.12 | -0.15 | -0.03 | 0.54 | Upgrade |
EPS (Diluted) | -0.05 | -0.12 | -0.12 | -0.15 | -0.03 | 0.51 | Upgrade |
Free Cash Flow | -42.5 | -51.29 | -98.53 | -23.37 | 0.28 | 180.17 | Upgrade |
Free Cash Flow Per Share | -0.13 | -0.16 | -0.33 | -0.08 | 0.00 | 0.61 | Upgrade |
Dividend Per Share | 0.088 | 0.088 | - | - | - | - | Upgrade |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade |
Operating Margin | -445.47% | -527.75% | -435.95% | -588.73% | -30.13% | 82.65% | Upgrade |
Profit Margin | -216.31% | -423.90% | -263.86% | -473.40% | -26.32% | 69.44% | Upgrade |
Free Cash Flow Margin | -538.50% | -560.07% | -739.52% | -258.81% | 0.79% | 83.53% | Upgrade |
EBITDA | -34.42 | -47.59 | -57.45 | -52.74 | -10.69 | 178.3 | Upgrade |
EBITDA Margin | - | - | - | - | -29.89% | 82.66% | Upgrade |
D&A For EBITDA | 0.74 | 0.74 | 0.63 | 0.42 | 0.09 | 0.03 | Upgrade |
EBIT | -35.16 | -48.33 | -58.08 | -53.16 | -10.78 | 178.27 | Upgrade |
EBIT Margin | - | - | - | - | -30.13% | 82.65% | Upgrade |
Effective Tax Rate | - | - | - | - | - | 17.21% | Upgrade |
Revenue as Reported | 7.89 | 9.16 | 13.32 | 9.03 | 35.77 | 215.7 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.